**Core tip:** Endovascular therapy of hepatic artery stenosis using angioplasty and stenting can be performed by interventional radiologists and has good outcomes and safety record, reducing the need for surgical revascularization or re-transplantation. The Wingspan neurovascular stent is a new self-expanding stent that has good conformability, maneuverability and adequate radial resistance for this application.

INTRODUCTION
============

Hepatic artery stenosis (HAS) is a possible complication of orthotopic liver transplant (OLT) occurring in 3.1%-7.4% of patients\[[@B1]-[@B4]\]. HAS may progress to hepatic artery thrombosis (HAT), limiting graft perfusion and causing liver dysfunction and biliary ischemia. Traditionally, HAS was treated surgically with revascularization or re-transplantation, but endovascular treatments have become more commonplace in the last 3-4 decades. Hepatic angiography can definitively diagnose HAS and allows simultaneous treatment using percutaneous transluminal angioplasty (PTA), stenting, or a combination of both. However, significant arterial tortuosity and kinking can occur in a subgroup of patients, associated with poorer technical success, poorer patient outcomes, and a higher complication rate\[[@B2],[@B5]-[@B8]\]. Stent placement may improve outcomes in these patients, but stent delivery and deployment in tortuous anatomy can be difficult. New neurovascular stents have recently become available that may suit this application well as they are intended for use in tortuous intracranial anatomy. In a recent case of a patient with HAS after OLT, we utilized a neurovascular Wingspan stent (Stryker, Kalamazoo, MI, United States) to treat a tight stenosis around a hairpin bend. Neurointerventional devices have been used for the treatment of visceral aneurysms\[[@B9]\], but so far no reports are available for their use in stenotic visceral arteries. To our knowledge this is the first report of successful implantation of the Wingspan neurovascular stent in a transplant hepatic artery.

CASE PRESENTATION
=================

Chief complaints
----------------

Nausea, vomiting, weakness, and lethargy.

History of present illness
--------------------------

A 47-year-old woman with a history of alcoholic cirrhosis status post OLT and a complex post-transplant course had elevated liver function tests (LFTs) 69 d post-transplant.

History of past illness
-----------------------

The patient has a history of decompensated cirrhosis secondary to alcohol use underwent OLT at our institution. Her Model for End-stage Liver Disease score was 33, and she received a liver allograft from a 61-year-old deceased donor who died from complications of a cerebrovascular accident. The arterial anastomosis was formed between the donor celiac axis and a branch patch of the recipient's proper hepatic and gastroduodenal arteries. Initial graft function was good. Post-transplant course was complicated by failure to thrive, pneumonia with respiratory failure, intractable nausea and vomiting, and chronic kidney disease on dialysis. She remained an inpatient during her convalescence, and on POD \#69 she developed newly elevated LFTs.

Physical examination
--------------------

Vitals: within normal limits; General: Alert, oriented, and cooperative; Neck: Tracheostomy in place, healing well; Heart: Regular rate and rhythm, no murmurs; Lungs: Clear to auscultation, mildly decreased lung sounds at bases; Abdomen: Soft, non-tender, bowel sounds normal, no masses, no organomegaly, chevron incision. Gastrojejunostomy tube in place; Extremities: No edema, pulses normal; Skin: Skin color, texture, and turgor are normal.

Laboratory examinations
-----------------------

At 69 d post-transplant, the patient's LFTs became elevated (Figure [1](#F1){ref-type="fig"}).

![Liver function tests from the time of liver transplant. PTA: Percutaneous transluminal angioplasty; LFT: Liver function test; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AP: Antipsychotics.](WJG-26-448-g001){#F1}

Imaging examinations
--------------------

Initial Doppler ultrasound (DUS) showed patent vasculature, but was notable for a subtle *parvus et tardus* waveform and relatively low resistive indices throughout the hepatic artery, ranging from 0.4 to 0.5 (Figure [2A](#F2){ref-type="fig"}). A liver biopsy showed no evidence of acute T-cell mediated rejection, biliary obstruction, or ischemic injury. Ultimately, a computed tomography (CT) angiogram of the abdomen and pelvis performed on post-transplant day 90 identified a diminutive and irregular proper hepatic artery, which appeared smaller when compared to 1 mo prior (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}).

![Images of doppler ultrasound in the main hepatic artery. A: Doppler ultrasound in the main hepatic artery prior to intervention (day 80 post-transplant) demonstrating *parvus et tardus* waveform with low resistive index and low peak systolic velocity; B: After stenting (day 115 post-transplant, day 15 post stenting) showing normal waveform, normal peak systolic velocity, and normal resistive index.](WJG-26-448-g002){#F2}

![Images of computed tomography angiogram. A: Computed tomography angiogram performed 60 d post-transplant showing small and irregular proper hepatic artery with stenosis (arrow); B: Ninety days post-transplant, showing small and irregular proper hepatic artery with stenosis (arrow); C and D: Hepatic artery angiography on post-transplant day 91 revealed a tight stenosis around a hairpin turn (white arrow) treated effectively with percutaneous transluminal angioplasty.](WJG-26-448-g003){#F3}

FINAL DIAGNOSIS
===============

History of liver transplant with elevated LFTs and imaging findings concerning for recurrence of HAS.

TREATMENT
=========

On post-transplant day 91, a hepatic artery angiogram was performed *via* right common femoral artery access, which revealed an approximately 70% stenosis around a hairpin bend in the hepatic artery. Low-pressure angioplasty using 1:1 sizing was performed using a 3 mm × 20 mm Sterling balloon (Boston Scientific, Marlborough, MA, United States), which relieved the stenosis and improved flow (Figure [3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). The patient's LFTs down-trended from post-transplant days 92 to 99, but then resumed an uptrend (Figure [1](#F1){ref-type="fig"}), and re-stenosis was suspected. The patient returned to the angiography suite on post-transplant day 100, and angiography from right common femoral access demonstrated recurrence of an approximately70% stenosis around the same hairpin bend (Figure [4A](#F4){ref-type="fig"}). Repeat PTA was performed using a 3 mm × 20 mm Coyote balloon (Boston Scientific, Marlborough, MA, United States) over a 014 BMW wire (Abbott, Santa Clara, CA, United States) through a 7Fr RDC guide catheter (Terumo, Somerset, NJ, United States). This angioplasty improved the stenosis (Figure [4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}), but given the failure of the prior angioplasty in the same location, a decision was made to stent the stenotic area. The patient was anticoagulated with 3000 units of IV heparin. Coaxial support proximal to the lesion was achieved by passing a Navien 058 Intracranial Support catheter (Covidien Vascular Therapies, Mansfield, MA, United States) into the hepatic artery through the 7Fr RDC guide catheter. Access across the stenosis was achieved using a 0.014 Synchro Support Pre-Shaped exchange-length guidewire (Stryker, Kalamazoo, MI, United States) and a Prowler Select Plus microcatheter (Codman Neurovascular, Raynham, MI, United States). Due to the small size and tortuosity of the vessel, we considered coronary and neurovascular stents. We chose a 4.5 mm × 20 mm Wingspan neurovascular self-expanding bare metal stent (Stryker, Kalamazoo, MI, United States) to closely approximate the size of the artery proximal and distal to the stenosis. The microcatheter was removed over the microwire, and the Wingspan stent delivery system was advanced across the lesion and deployed (Figure [4D](#F4){ref-type="fig"} and [E](#F4){ref-type="fig"}). No post-implantation balloon dilation was performed. Post intervention angiogram showed marked improvement in the luminal diameter with brisk flow of contrast through the stent and into the right and left hepatic arteries (Figure [4F](#F4){ref-type="fig"}).

![Angiography on day 100 post-transplant. A: Angiography on day 100 post-transplant showed recurrent hepatic artery stenosis (arrow, insert); B and C: Balloon dilation (arrowheads) performed within the hairpin turn did not resolve the stenosis (C, arrow); D: Synchro support wire passed distally for stability (arrowhead) with advancement of Navien support catheter (arrow); E: Wingspan stent advanced around hairpin. Stent end markers are easily visualized (double head arrows); F: Post-stent angiography demonstrates resolution of the stenosis (arrow) and brisk flow into the hepatic arteries.](WJG-26-448-g004){#F4}

OUTCOME AND FOLLOW UP
=====================

The patient's LFTs declined immediately post procedure and have been normal at 2 mo follow-up (Figure [1](#F1){ref-type="fig"}). Her LFTs remained stable except for a period of 4 d (post-transplant days 114-118) during which she was re-admitted for an unrelated illness. Post procedure the patient was placed on a heparin drip to bridge to warfarin and a single antiplatelet agent (aspirin). DUS performed 1 day and 15 d post-intervention demonstrated improved hepatic arterial waveforms with normal peak systolic velocities and resistive indices (Figure [2B](#F2){ref-type="fig"}). Two months later, the patient is well and remains on warfarin and aspirin.

DISCUSSION
==========

Endovascular procedures are now a common option for treatment of HAS in liver transplant patients. The first cases reported in 1989-1990\[[@B5],[@B10]\] usd PTA with good technical success and clinical benefit. However, vessel tortuosity and arterial kinking were identified as significant impediments to intervention because they prevented crossing of the stenosis\[[@B5]\]. Even with more modern techniques and devices, vessel tortuosity remains an important factor in procedure success and clinical outcome. Saad et al\[[@B6]\] showed in a retrospective study of 42 patients undergoing intervention for HAS that the technical success rate for angioplasty in vessels with kinks *vs* without kinks was substantially lower (14% *vs* 94%) and the complication rate was higher (29% *vs* 10%). They recommended avoiding endovascular treatment in kinked vessels and treating instead with surgical revascularization, an opinion which has been echoed by others\[[@B7]\]. In another study, vessel tortuosity prevented technical success in 10% of patients\[[@B8]\]. In the case described here, we encountered a stenosis with significant vessel tortuosity (a tight hairpin bend), which failed initial angioplasty but was successfully treated with neurovascular stent placement.

Stenting in the transplant hepatic artery is described in a number of case studies. A case series of 4 patients treated for HAS (*n* = 2) and HAT (*n* = 2) using Wallstents and Palmaz stents (Cordis, Warren, NJ, United States) showed patency at 18-25 mo follow-up with no need for re-transplantation\[[@B11]\]. A retrospective study of a series of 14 patients who received coronary stents for HAS showed 78% stent patency at 12 mo\[[@B12]\]. A separate case report also described the use of a coronary stent for HAS, which was successful at 4 mo follow-up\[[@B13]\]. A single-institution, retrospective study of stenting in 30 HAS patients showed primary patency of 90% at 1 year\[[@B7]\]. A number of larger studies evaluated stenting compared to angioplasty alone. A meta-analysis of 263 liver transplants in 257 patients who underwent 147 PTA and 116 stent placements showed equivalent technical success, complications, patency, survival, and requirement for reintervention. The authors concluded that the use of stents should be based on anatomical considerations such as kinked vessels or in cases where PTA is attempted but results in restenosis shortly thereafter\[[@B14]\]. A single-center retrospective study of 42 patients treated with either PTA alone (*n* = 17) or primary stenting (*n* = 25) showed patency at 12 mo of 40% *vs* 78% and a time to reintervention of 51 d *vs* 105.8 d, suggesting better outcomes for primary stenting\[[@B15]\]. The long-term outcomes of endovascular treatment were evaluated in a single-center retrospective study of 30 HAS patients treated with PTA + stent (90%) or PTA alone (10%). This study showed restenosis in 33% of all treated patients and combined patency at 12 mo of 68% that was maintained at 5 years\[[@B8]\].

The complications of PTA and stenting in HAS have been well described. A retrospective single-center study in a large transplant center examined 79 patients with HAS who were treated with PTA alone (33%) or stenting (66%). Major complications occurred in 7.5% of cases and consisted of arterial dissection or rupture. Complications were treated endovascularly in 6 of 8 cases, but these patients had a much higher rate of progression to HAT. Severe vessel tortuosity was a risk factor for complications, present in 75% of those with complications, but only in 34.6% of those without complications\[[@B2]\].

Stenting the transplant hepatic artery results in robust clinical outcomes, has an acceptable complication rate, and is recommended especially in tortuous vasculature. However, vessel tortuosity increases the technical challenge of the procedure in several ways: (1) Crossing a stenosis with the stent deployment system is more technically challenging; (2) The stent must be flexible enough to track around tortuous vessels and conform to the vessel tortuosity; and (3) The stent must have adequate radial force to maintain patency of the stenosis. Thus far, all studies in this field have used coronary stents or Wallstents\[[@B8],[@B11]-[@B15]\] and some authors recommend balloon-expandable stents for better deployment control\[[@B15]\].

Additional stent options may address the challenges of stent use in tortuous anatomy. In our case, a self-expanding Wingspan neurovascular stent was used. The Wingspan stent has a high radial force and low bending moment\[[@B16]\] compared to other neurovascular stents, which allows it to cross and conform to tortuous vessels but also resist stenotic lesions. The Wingspan is available in a variety of sizes appropriate for this application from 2.5-4.5 mm diameter and 9-20 mm length. The stent diameter is sized to exceed the diameter of a normal patent vessel by 0.5-1 mm\[[@B17]\]. To our knowledge the use of Wingspan stents has not been reported previously in extra-cranial applications. However, there is precedent for using neurointerventional stents in visceral arterial applications with good outcomes\[[@B9]\]. In intracranial applications, the Wingspan stent has been used with good safety and efficacy\[[@B18]-[@B20]\].

Post procedure management varies widely between centers but generally includes a course of anti-coagulation and/or anti-platelet therapy and imaging of the treated vessel for assessment of re-stenosis. Recent reports advocate the use of dual-antiplatelet therapy for 3-6 mo\[[@B7],[@B15]\] followed by low dose aspirin indefinitely. For monitoring of patency, one approach has been contrast CT at 3 mo and DUS at 1 d, 1 mo, 6 mo, and yearly thereafter\[[@B8]\].

CONCLUSION
==========

HAS is an important complication of liver transplantation that is associated with significant morbidity and potential for graft loss. The use of endovascular therapies has significantly reduced the need for surgical revascularization and re-transplantation. Stenting in addition to PTA offers safe, durable outcomes but is technically challenging and prone to complications in tortuous vessels. Our experience with using the Wingspan neurovascular stent that is self-expanding, has good conformability, and adequate radial resistance indicates that this stent could be added to the armamentarium of interventionalists in the setting of a tortuous and stenotic transplant hepatic artery.
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